Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting

American Journal of Public Health

Volumn 102, Issue 11, 2012, Pages

  Drainoni, Mari Lynn ^a   Litwin, Alain H ^b   Smith, Bryce D ^c   Koppelman, Elisa A ^a   McKee, M Diane ^b   Christiansen, Cindy L ^a   Gifford, Allen L ^d   Weinbaum, Cindy M ^c   Southern, William N ^b  

^a BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE;

ADULT; ARTICLE; BLOOD; FEMALE; HEALTH INSURANCE; HEPATITIS C; HUMAN; INSURANCE; MALE; METHODOLOGY; PRIMARY HEALTH CARE; RACE; REMINDER SYSTEM; RISK FACTOR; STATISTICS;

ADULT; ALANINE TRANSAMINASE; CONTINENTAL POPULATION GROUPS; FEMALE; HEPATITIS C; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; MALE; PRIMARY HEALTH CARE; REMINDER SYSTEMS; RISK FACTORS;

EID: 84867494768     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2012.300659     Document Type: Article

References (25)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WK, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714
2. Kanwal F, Schnitzler MS, Bacon BR, Hoang T, Buchanan PM, Asch SM. Quality of care in patients with chronic hepatitis C virus infection. Ann Intern Med. 2010;153(4):231-239.
3. Ly K, Xing J, Klevens M, Jiles R, Ward J, Holmberg S. The growing burden of mortality from viral hepatitis in the US, 1999-2007. Paper presented at: annual meeting of the American Association for the Study of Liver Diseases, November 2011, San Francisco, CA.
4. Volk ML, Tocco R, Saini S, Lok AS. Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology. 2009;50(6):1750-1755.
5. Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatmentnaïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705-716.
6. Roblin DW, Smith BD, Weinbaum CM, SabinM. Hepatitis C virus screening practices and prevalence in an MCO, 2000-2007. AmJManag Care. 2011;17(8):548-555.
7. Wasley A, Finelli L, Bell BP, Alter MJ. The knowledge and behavior of HCV-infected persons identified in a national seroprevalence survey, United States, 2001-2004. Paper presented at: 12th International Symposium on Viral Hepatitis and Liver Disease, July 2006, Paris, France.
8. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR19):1-39.
9. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-1374.
10. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-1171.
11. US Dept of Veterans Affairs. Hepatitis C testing and prevention counseling guidelines for VA health care practitioners. Available at: http://www.hepatitis.va.gov/provider/guidelines/testing-prevention-counseling. asp. Accessed July 24, 2012.
12. Dienstag JL, McHutchinson JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology. 2006;130(1):225-230.
13. National Institutes of Health. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002. Hepatology. 2002; 36(suppl 1):S3-S20.
14. Ko YC, Ho MS, Chiang TA, Chang SJ, Chang PY. Tattooing as a risk of hepatitis C virus infection. J Med Virol. 1992;38(4):288-291.
15. Tumminelli F, Marcellin P, Rizzo S, et al. Shaving as potential source of hepatitis C virus infection. Lancet. 1995;345(8950):658.
16. Hayes MO, Harkness GA. Body piercing as a risk factor for viral hepatitis: an integrative research review. Am J Infect Control. 2001;29(4):271-274.
17. Conry-Cantilena C, VanRaden M, Gibble J, et al. Routes of infection, viremia and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med. 1996;334(26):1691-1696.
18. Tortu S, Neaigus A, McMahon J, Hagen D. Hepatitis C among non-injecting drug users: a report. Subst Use Misuse. 2001;36(4):523-534.
19. Zalumas J, Rose C. Hepatitis C and HIV in incarcerated populations: fights, bites, searches, and syringes! J Assoc Nurses AIDS Care. 2003;14(suppl 5): 108S-115S.
20. McGinn T, O'Connor-Moore N, Alfandre D, Gardenier D, Wisnivesky J. Validation of a hepatitis C screening tool in primary care. Arch Intern Med. 2008;168(18):2009-2013.
21. Zuniga IA, Chen CC, Lane DS, Allmer J, Jimenez- Lucho VE. Analysis of a hepatitis C screening programme for US veterans. Epidemiol Infect. 2006;134(2): 249-257.
22. Litwin AH, Smith BD, Drainoni ML, et al. Primary care-based interventions are associated with increases in hepatitis c virus testing for patients at risk. Dig Liver Dis. 2012;44(6):497-503.
23. Agency for Health Care Research and Quality. Accelerating Change and Transformation in Organizations and Networks (ACTION): field partnerships for applied research. Available at: http://www.ahrq.gov/research/action.htm. Accessed July 24, 2012.
24. Southern WN, Drainoni M, Smith BD, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat. 2011;18(7): 474-481.
25. Stata, Version 10.0. College Station, TX: StataCorp LP; 2007.